International audienceBackground: Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor ( VEGF) pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared bevacizumab maintenance versus observation alone after induction chemotherapy with FOLFIRI plus bevacizumab. Objective: We evaluated the impact of SNPs of VEGF-A, VEGF receptors ( VEGFR-1, VEGFR-2), and hypoxia inducible factor-1α ( HIF-1α) on tumor control duration (TCD), overall survival (OS), progression-free survival (PFS), and duration of first chemotherapy free-intervals (CFI). Patients and methods: We included 314/49...
Insights into the molecular genetics of cancer have fueled the development of so-called targeted th...
Abstract Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colore...
Background: Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatme...
International audienceBackground: Several studies have reported the impact of single nucleotide poly...
PURPOSE: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mC...
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identifi...
The aim of this study is to evaluate the influence of germline vascular endothelial growth factor (V...
Introduction: Addition of BV to first-line irinotecan plus 5FU improves PFS and OS of mCRC pts. Mea...
<div><p>Purpose</p><p>The potential impact of different SNPs of <i>VEGF/VEGFR</i> pathway on the cli...
International audienceBACKGROUND: Over 50% of colorectal cancer (CRC) patients develop metastases. T...
Insights into the molecular genetics of cancer have fueled the development of so-called targeted th...
Abstract Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colore...
Background: Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatme...
International audienceBackground: Several studies have reported the impact of single nucleotide poly...
PURPOSE: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mC...
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identifi...
The aim of this study is to evaluate the influence of germline vascular endothelial growth factor (V...
Introduction: Addition of BV to first-line irinotecan plus 5FU improves PFS and OS of mCRC pts. Mea...
<div><p>Purpose</p><p>The potential impact of different SNPs of <i>VEGF/VEGFR</i> pathway on the cli...
International audienceBACKGROUND: Over 50% of colorectal cancer (CRC) patients develop metastases. T...
Insights into the molecular genetics of cancer have fueled the development of so-called targeted th...
Abstract Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colore...
Background: Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatme...